Mer Scott
Test por , creado hace más de 1 año

PHCY310 Test sobre L16 Therapeutics of Asthma, creado por Mer Scott el 12/04/2019.

8
0
0
Mer Scott
Creado por Mer Scott hace más de 5 años
Cerrar

L16 Therapeutics of Asthma

Pregunta 1 de 8

1

Clinical practice guidelines, meta-analysis, and systematic reviews are the highest ranked forms of evidence.

Selecciona uno de los siguientes:

  • VERDADERO
  • FALSO

Explicación

Pregunta 2 de 8

1

Māori are 3.4 times, and Pacific peoples 3.9 times, more likely to be admitted to hospital with asthma than Europeans or other New Zealanders.

Selecciona uno de los siguientes:

  • VERDADERO
  • FALSO

Explicación

Pregunta 3 de 8

1

When diagnosing asthma there is no single “gold standard” test, and we must assess the pattern of (wheezing, breathlessness, chest tightness, and coughing, particularly at or in the morning). We can also measure on more than one occasion, and assess to inhaled bronchodilator +/- inhaled corticosteroid.

Arrastra y suelta para completar el texto.

    signs and symptoms
    night
    early
    expiratory airflow
    response

Explicación

Pregunta 4 de 8

1

Ideal PEFR values depend on height and sex.

Selecciona uno de los siguientes:

  • VERDADERO
  • FALSO

Explicación

Pregunta 5 de 8

1

Which of these is NOT a principle of asthma treatment?

Selecciona una de las siguientes respuestas posibles:

  • Avoid triggers

  • Making an asthma plan

  • Drugs to improve ventilation

  • Drugs to decrease inflammation

  • Avoid exercise

Explicación

Pregunta 6 de 8

1

Goals of asthma treatment are about maintaining long-term control using the amount of medications and adverse effects.
We want to prevent chronic , require infrequent use ( or fewer days/week) of SABA, maintain normal or near-normal function and maintain levels. We should assure patients’ and families’ with asthma care. We also want to prevent exacerbations, the need for , and prevent progressive of lung function.

Arrastra y suelta para completar el texto.

    least
    minimising
    symptoms
    2
    pulmonary
    activity
    satisfaction
    hospitalisation
    loss

Explicación

Pregunta 7 de 8

1

Which of these is not a drug delivery device?

Selecciona una de las siguientes respuestas posibles:

  • Soft mist inhaler (SMI) - only with LAMA products in NZ

  • Nebuliser

  • Dry power inhaler (DPI)

  • Metered-dose inhaler (MDI) - spacer chamber

  • Dry mist inhaler (DMI)

Explicación

Pregunta 8 de 8

1

Treatment steps:
1. At initial diagnosis, all patients should use a , as required..
2. Add an if patients have symptoms for more than weeks. Often a big decision! (The usual dose in adults is /day.)
3. If control is not adequate, can be increased.
4. If control is not adequate, combine . ( can be used as a preventer and replace SABA.)

Patients can step up or down in order to achieve and maintain control.
Check adherence and inhaler at each step of the way!

Arrastra y suelta para completar el texto.

    SABA
    ICS
    two
    budesonide 400 mcg
    ICS dose
    ICS with a LABA
    Formoterol+budesonide
    technique

Explicación